Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

P. D. Molyneux, G. J. Barker, F. Barkhof, K. Beckmann, F. Dahlke, M. Filippi, M. Ghazi, D. Hahn, D. MacManus, C. Polman, C. Pozzilli, L. Kappos, A. J. Thompson, K. Wagner, T. Yousry, D. H. Miller

Research output: Contribution to journalArticlepeer-review


Background: The recently completed placebo-controlled multicenter randomized trial of interferon beta-1b (Betaferon) in 718 patients with secondary progressive MS shows significant delay of disease progression and reduction of relapse rate. This study provides an opportunity to assess the level of relationship between clinical and MRI outcomes in this cohort of patients with secondary progressive MS. Methods: Brain T2-weighted lesion volume was measured annually in all available patients, with visual analysis to identify any new or enlarging (active) T2 lesions at each annual time point. A subgroup of 125 patients had monthly gadolinium-enhanced, T1-weighted imaging at months 0 to 6 and 18 to 24. Relapses were documented and expanded disability status scale (EDSS) was measured every 3 months. Results: For the annual MRI outcomes, a significant but modest correlation was identified between the change in T2 lesion volume from baseline to the final scan and the corresponding change from baseline in EDSS (r = 0.17, p <0.0001). There were significant correlations between the cumulative number of active T2 lesions and 1) change in EDSS (r = 0.18, p <0.0001) and 2) relapse rate (r = 0.24, p <0.0001). In the subgroup of 125 patients undergoing monthly imaging, MRI lesion activity was correlated with relapse rate over months 0 to 24 (r = 0.24, p = 0.006) but not with change in EDSS. Conclusions: These results confirm that the clinical-MRI relationships previously identified in relapsing-remitting MS still are apparent in the secondary progressive phase of the disease and support the use of MRI as a relevant outcome measure. In view of the relatively modest nature of the correlations, it seems unwise to rely on such MRI measures alone as primary efficacy variables in secondary progressive MS trials.

Original languageEnglish
Pages (from-to)2191-2197
Number of pages7
Issue number12
Publication statusPublished - Dec 26 2001

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS'. Together they form a unique fingerprint.

Cite this